Published • loading... • Updated
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
- Astellas announced that the first patient received setidegrasib in a Phase 3 study for previously treated KRAS G12D-mutated advanced non-small cell lung cancer.
- The randomized, open-label study will compare setidegrasib with docetaxel in patients whose disease progressed after platinum-based chemotherapy and checkpoint inhibitor therapy.
- Setidegrasib is an investigational protein degrader designed to eliminate the disease-driving KRAS G12D protein.
- Astellas plans to enroll approximately 356 patients across multiple countries.
Insights by Ground AI
40 Articles
40 Articles
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC -- Milestone marks second Phase 3 study of setidegrasib initiated within six months
·Indiana, United States
Read Full ArticleCoverage Details
Total News Sources40
Leaning Left6Leaning Right6Center21Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 18%
C 64%
R 18%
Factuality
To view factuality data please Upgrade to Premium
